Evommune files for $100M IPO

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States. Our most advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons. Dysregulated MRGPRX2 activity can play a key role as both a catalyst and perpetuator of disease pathogenesis across a multitude of systemic chronic inflammatory diseases. By targeting MRGPRX2, we believe EVO756 is the only dual mechanism clinical approach that modulates both mast cells and peripheral sensory neurons, representing a new potential therapeutic option to reduce inflammation and provide rapid relief of itch (pruritus).
less

IPO DataIPO File Date 10/09/2025
Offer Price
Price Rangen/a
Offer Shares (mm) n/a
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only

UnderwritersMorgan Stanley
Leerink Partners
more

Company DataHeadquarters Palo Alto, CA, United States
Founded 2020
Employees at IPO 45
Websitewww.evommune.com

IPO News for EvommuneUS IPO Weekly Recap: 6 IPOs debut, pipeline grows, despite government shutdown10/10/25
Chronic inflammatory disease biotech Evommune files for a $100 million IPO10/09/25

https://www.renaissancecapital.com/Profile/EVMN/Evommune/IPO